Wegovy Alternatives & Comparison
Wegovy (semaglutide) set beside Zepbound, Saxenda, Foundayo: how each works, what its trials measured, what it costs, and who sells it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
These are the drugs people weigh against Wegovy. The Wegovy drug guide covers Wegovy itself, the Wegovy cost page covers its price.
Wegovy Alternatives Compared
Adds GIP to the GLP-1 action, and head-to-head data puts average weight loss higher
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects.
One head-to-head settles the weight question but not the whole question. SURMOUNT-5 put Zepbound at −20.2% against Wegovy's −13.7% at 72 weeks, a 6.5-point gap under one protocol. Wegovy answers a different question: SELECT cut major cardiovascular events 20%. Tirzepatide's own outcomes trial, SURPASS-CVOT (NEJM, December 2025), was run in type 2 diabetes, and the cardiovascular indication it earned sits on the Mounjaro label, not Zepbound's. Cash pricing is close: $349 a month for Wegovy through NovoCare, $299–$449 for Zepbound through LillyDirect. So the split is magnitude of weight loss against proven event reduction, and that is a prescriber's call, not a table's.
Full Zepbound vs Wegovy comparison →The daily GLP-1 injection that came first, with a long approval history behind it
Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours.
Both come from Novo Nordisk, both are for weight management, and Saxenda is the older drug in every sense. Liraglutide's ~13-hour half-life forces daily injection where semaglutide's ~7 days allows weekly. Wegovy has SELECT and its MACE −20%; Saxenda has no dedicated obesity outcomes trial, only LEADER's −13% at a diabetes dose. The commercial gap is stark: $349 a month through NovoCare against well over $1,000 at retail for Saxenda, with no comparable cash program. There are few arguments left for Saxenda.
Full Saxenda vs Wegovy comparison →Daily oral GLP-1, nothing to inject
Orforglipron is not built as a peptide. It is a small organic molecule that binds the GLP-1 receptor and switches it on directly.
STEP-1 reported −14.9% at 68 weeks for Wegovy; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo. The figures are close enough that delivery and cost may decide it, but Wegovy carries the completed cardiovascular outcome, MACE −20% in SELECT, and Foundayo has no MACE data yet. That asymmetry matters: one has been shown to prevent events, the other to reduce weight. Wegovy costs $349 a month through NovoCare; Foundayo costs $149–$349 through LillyDirect.
Full Foundayo vs Wegovy comparison →An oral option outside the GLP-1 class, usually picked on cost or GI tolerance
Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, which release alpha-MSH to reduce appetite, but POMC neurons also release beta-endorphin, which feeds back onto mu-opioid receptors on the POMC neurons themselves and shuts them off — limiting the appetite-suppressing effect.
The widest cost-to-effect spread in this market. STEP-1 reported −14.9% at 68 weeks for Wegovy; COR-I reported −6.1% at 56 weeks for Contrave. Contrave runs about $99 a month through the Currax direct program against Wegovy's $349 through NovoCare. The mechanisms differ entirely: GLP-1 satiety against an opioid antagonist plus bupropion working on reward and craving. Contrave is also what many insurers make you fail first, which makes this comparison less hypothetical than it sounds.
Full Contrave vs Wegovy comparison →Established oral combination outside the class, for anyone avoiding injectables
Qsymia combines two mechanisms in a single capsule.
STEP-1 reported −14.9% at 68 weeks for Wegovy; EQUIP reported −10.9% at 56 weeks for Qsymia at its top 15/92 mg dose, which is closer than most people expect. Qsymia runs about $100–$200 a month, and generic phentermine plus topiramate can be around $50, against Wegovy's $349 through NovoCare. Topiramate carries real teratogenic risk, which is why the pregnancy questions on a Qsymia intake are not a formality.
Full Qsymia vs Wegovy comparison →Drug facts on this page were last verified against each drug's FDA label and trial record.
Compare compounded Semaglutide providers
Compounded semaglutide sits at a middle figure of $199/month across 726 price points in the register, spanning $49 to $599. The partners below are ordered by our partner economics.
Compare compounded Tirzepatide providers
Compounded tirzepatide sits at a middle figure of $250/month across 697 price points in the register, spanning $69 to $849. The partners below are ordered by our partner economics.
Compare every Wegovy provider
Current price, verification status, product form and the states each seller ships to, all on one screen.